This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Viral Vector Development Market

Market Insights on Viral Vector Development covering sales outlook, demand forecast & up-to-date key trends

Viral Vector Development Market By Vector Type (Retro-viral Vectors, Adeno-viral Vectors, Adeno-associated Viral Vectors, and other types), Disease (Cancer, Genetic Disorders, Infectious Diseases), End Use (Pharma & Biopharma Companies, Research Institutes) & Region - Forecast 2022 - 2032

Viral Vector Development Market Outlook (2022-2032)

[326 Pages Report] The viral vector development market is estimated to grow at a robust CAGR of 18.2%, reaching nearly US$ 3.2 Bn by 2032 from US$ 534 Mn in 2021.

Hereditary diseases have long been regarded as incurable by the medical community and traditional medicine scientists. However, the advent of genetic therapy started a new era in medicine, having the potential to correct the defective genes that are responsible for such hereditary diseases.

For this technique, Adeno-associated virus or AAV expression vector is commonly used as a vehicle in the gene therapy process.

By virtue of such gene therapy has immense possibilities in the medical sciences, the viral vector products are turning out to be market ready. There are a number of biopharmaceutical developers indulged in the production and supply, which might be targeted at balancing the demand-supply ratio.

Attributes

Details

Viral Vector Development Market CAGR (2022-2032)

18.2%

Viral Vector Development Market (2027)

US$ 1.4 Bn

Viral Vector Development Market Attraction

Increased government spending on gene therapy technology for developing new vaccines is expected to raise the demand for viral vector products in the healthcare research sector.

Customize this Report

Let us know your requirement to get
100% FREE customization

What is the Covid-19 Impact on Viral Vector Development Market?

Though the global market in all commodities was disrupted abruptly in the pandemic years following the outbreak of Cocvid-19 infections, it provided immense opportunities for the growth of the viral vector CDMO market on a global scale. Many research institutes and private biopharmaceutical companies participated in finding a treatment solution and vaccine as soon as possible for curbing the rapid spread of the causal pathogen.

The development of any type of countermeasure required the culture of a novel coronavirus, increasing the demand for viral vector products to do so. The private manufacturing companies, along with public facilities developing viral vectors, were at the forefront of producing and supplying all types of viral vectors, including recombinant adenoviral vectors.

At the present time, there are several companies and state organizations that have successfully found the AAV-based vaccine for preventing the infection of Covid-19. However, there is also a lot of research going on for finding out a more effective vaccine for the Covid-19 that will drive the global viral vector market during the forecast years.

What is the Present Dynamics of the Global Viral Vector Development Market?

“For repairing repressing and replacement of dysfunctional genes in human cells or tissues requires gene therapy bring back the disorder to normal level. For inducing gene it is cultured by viral vector technology that has emerged as a substantial market for many private players.”

Mostly two types of approaches are undertaken for the use of viral vectors in the gene therapy-induced treatment process. Scaling out of adherent cell systems is one technique widely used in 2D planer technologies is the prominent unit in the market until the market analysis time.

However, in the coming days, the 3D suspension cell cultures are stirred, or bioreactors are getting more popular for suspension AAV production by various segments.

In the aftermath of the Covid-19 pandemic, the government of many nations realized the establishment of research institutes in the field of gene therapy and vaccine development.

This trend of investing increasingly in biotech and pharmaceutical companies is predicted to increase the viral vector products market on a global scale.

What are the Major Challenges Experienced by the Viral Vector Development Market Players?

Requirement for final products of clinical-grade and thoroughly polished has introduced the deployment of very complex procedures. Such high-end technological procedures incur a heavy investment for the viral vector companies during the initial set of production units.

Stringent government regulations for approving any new development concerned with the healthcare sector still remain the main hindrance for the viral vector development for various purposes in a rapid manner.

The availability of sufficient good laboratories for the testing and approval of critical raw materials is certainly the limiting factor for the growth of the global viral vector development market.

Some of the big companies have captured the global market with a higher investment in technology and marketing strategies. Biontech viral vector is such a renowned product in the present market, posing as a major challenge for the new companies and regional players.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Adjacent Viral Vector Development Market

Viral Vector Development Market:

Attributes

Viral Vector Development Market

CAGR (2022 - 2032)

18.2%

Market Value (2027)

US$ 1.4 Bn

Growth Factor

Emerging novel viruses with the potential to infect the human beings is a rising concern. To develop proper vaccine for such diseases the demand for AAV based vaccine has increased manifold.

Opportunity

The trend of using suspension AAV production in developing vaccines against viral disease is poised to increase in the coming years.

Key Trends

With the rapid advancement in medical science viral vector companies are upgrading their facilities to produce high end products according to the demand.

Gene Therapy Market:

Attributes

Gene Therapy Market

CAGR (2022 - 2032)

25%

Market Value (2027)

US$ 2.1 Bn

Growth Factor

Rising burden of neurological diseases has increased the demand for gene therapies. The lentiviral reporter vectors is the prominent segment with highest CAGR.

Opportunity

The wide use of lentiviral vector crispr in gene therapy has positioned this segment in the most attractive category of the gene therapy market.

Key Trends

The nucleotide based non-viral segment is overtaking the market of common viral vectors. This segment occupies the largest share of the global gene therapy market.

Plasmid DNA Manufacturing Market:

Attributes

Plasmid DNA Manufacturing Market

CAGR (2022 - 2032)

19.5%

Market Value (2027)

US$  360 Mn

Growth Factor

Increased prevalence of cancer cases on a global scale is the major reason for the growth of the plasmid DNA manufacturing market along with the inducible shRNA lentiviral vector.

Opportunity

Continuous research activities carried out to increase the applicability of AAV rep cap plasmids is poised to create new opportunities for the global market.

Key Trends

In recent years use of bacteria technique instead of ADVAC viral vector technology for the purification of Plasmid DNA has increased. This segment is estimated to experience a rapid growth during the forecast period.

Demand for viral vector services is growing as these help in development of vaccines. Viral Vector are mostly deployed for the development of vaccines for diseases caused by virus or pathogens. In the past decade more than 25% of the total viral vector products were assigned in the field of vaccine development segment.

Easier manufacturing processes and a wide immune response of the technology are some if its advantages creating a huge requirement viral vector process development in the production of vaccines.

What is the Growth Outlook for the Viral Vector Development Market in Different Segments?

Among all the types of viral vectors, Adeno-associated viral vectors or AAV expression vectors is the most commonly used segment dominating the market.

Nearly 20% of the total revenue generated by the global viral vector market comes through the demand and usage of adeno-associated viruses in clinical trials of several vaccines and medicines.

The use of AAV vector vaccines is also rising remarkably owing to its higher accuracy and proven records while the development of vaccines.

The other most used type of viral vector is the Adeno-viral vectors that have a higher potential of inducing humeral and T-cell response. As the Adeno-viral vectors are considered safer than the AAV rep cap plasmids so, there it is in higher demand for use as a tool to disrupt the host genome present in human cells.

What are the Major Diseases Involving the Viral Vector Development Market for Treatment?

Different types of viruses have proven to be the ideal vector for developing gene therapies for cancer treatment. Till now cancer segment has dominated the viral vector process development market worldwide as per several end users.

According to a market estimate, nearly 37% of the viral vector products are used for CAR-T cell therapies used in hematologic malignancies.

On the other hand, genetic disorders such as hemophilia, lipoprotein lipase deficiency disease, and adenosine deaminase-severe combined immunodeficiency require ADVAC viral vector technology for the treatment and control.

As the private pharmaceutical companies focus more on the production of medicines for the genetic disorder categories by the method of viral vector cloning so this segment is also a significant contributor to the growth of the global market.

Which End Users of the Global Viral Vector Development Market have the Maximum Growth Potential?

Despite the presence of several private biopharmaceutical players involved in research for developing vaccines and medicines for viral diseases, the research institutes dominated the market as end users of several types of viral vectors until the previous analysis period research institutes funded by government organizations of various countries covered a revenue share of up to 60% in the total revenue generated by common viral vectors available in the market.

Hopefully, many private pharmaceutical and biotechnology companies are indulging in the research and development of medicines for marketing purposes. This increased use of CDMO viral vectors is predicted to bring in necessary demand from private players in the coming years.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

What is the Performance of Viral Vector Development Market in Different Geographical Regions?

Until the previous years covered by market analysis reports, North America dominated the global viral vector development market by acquiring nearly 50% of the revenue share.

As the major amount of research and development in the field of advanced genetic therapies, the requirement for viral vector CDMO is highest in this region. United States is the leading country of this region and world that contributes at a remarkable amount in revenue generation by ADVAC viral vector technology services.

The growing investment by governments of Asia Pacific countries for the development of biotech and disease diagnosis regional research facilities has increased the demand for viral vector products considerably.

As per the market analysis report, the Asia Pacific region is going to experience the highest growth potential in the global viral vector development market.

Accelerated grant of requests to establish viral vector companies by several private players is supposed to be the main reason for the rapid growth of the regional viral vector market.

Also, with the strengthening of the medical infrastructure and rising awareness about gene therapy and AAV-based vaccine, the region is growing by more than average global CAGR.

The European nations such as Russia, Germany, and United Kingdom (UK) are also significant contributors to the global viral vector development market. Due to the presence of a number of leading players Europe region supplies common viral vectors around the world.

How is the Competitive Landscape for the Viral Vector Development Market?

By the emergence of a number of players in the field of viral vector CDMO and plasmid DNA manufacturing the market has turned very competitive in recent years. Expansion of manufacturing facilities is the foremost strategy adopted by the key companies to remain ahead of their competitors. Acquisition of small sized regional players is a cost effective method for the rapid expansion and capacity building for viral vector process development for the manufacturers.

What are the Recent Developments in the Field of Viral Vector Development Market?

  • The Germany based viral vector manufacturer, CDMO expanded its business activity in February 2020 by establishing a manufacturing unit in US. This unit at Massachusetts established by an investment of US$ 150 Mn is expected to capture the market of North America by supplying CDMO viral vector.
  • The viral vector manufacturing company named Groupe Novasep SAS was acquired by Thermo Fisher Scientific, in January 2021. This acquisition is anticipated to increase the capacity and Thermo Fisher scientific viral vector services in North America and beyond.

Key Players

Key Segments

By Vector Type:

  • Retro-viral Vectors
  • Adeno-viral Vectors
  • Adeno-associated Viral Vectors
  • Others

By Disease:

  • Genetic Disorders
  • Infectious Diseases
  • Others

By End Use:

  • Pharma & Biopharma Companies
  • Research Institutes
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa (MEA)

Frequently Asked Questions

The viral vector development market is estimated to record a CAGR of 18.2% during the forecast period.

The viral vector development market is predicted to be valued at US$ 3.2 Bn by 2032.

The global viral vector development market was valued at US$ 534 Bn in 2021.

North America accounts for the largest revenue in the global viral vector development market accounting for up to 50% of the total revenue.

Asia Pacific region is predicted to witness the highest CAGR in the viral vector development market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Viral Vector Development Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type, 2022-2032

        5.3.1. Retro-viral Vectors

        5.3.2. Adeno-viral Vectors

        5.3.3. Adeno-associated Viral Vectors

        5.3.4. Other Types

    5.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Type, 2022-2032

6. Global Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Disease

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Disease, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease, 2022-2032

        6.3.1. Cancer

        6.3.2. Genetic Disorders

        6.3.3. Infectious Diseases

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Disease, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Disease, 2022-2032

7. Global Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By End-use

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End-use, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-use, 2022-2032

        7.3.1. Pharma & Biopharma Companies

        7.3.2. Research Institutes

    7.4. Y-o-Y Growth Trend Analysis By End-use, 2017-2021

    7.5. Absolute $ Opportunity Analysis By End-use, 2022-2032

8. Global Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Disease

        9.2.4. By End-use

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Disease

        9.3.4. By End-use

    9.4. Key Takeaways

10. Latin America Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Argentina

            10.2.1.4. Chile

            10.2.1.5. Peru

            10.2.1.6. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Disease

        10.2.4. By End-use

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Disease

        10.3.4. By End-use

    10.4. Key Takeaways

11. Europe Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. Italy

            11.2.1.3. France

            11.2.1.4. U.K.

            11.2.1.5. Spain

            11.2.1.6. Russia

            11.2.1.7. BENELUX

            11.2.1.8. Rest of Europe

        11.2.2. By Type

        11.2.3. By Disease

        11.2.4. By End-use

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Disease

        11.3.4. By End-use

    11.4. Key Takeaways

12. Asia Pacific Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Rest of Asia Pacific

        12.2.2. By Type

        12.2.3. By Disease

        12.2.4. By End-use

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Disease

        12.3.4. By End-use

    12.4. Key Takeaways

13. Middle East and Africa Viral Vector Development Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Turkey

            13.2.1.4. Rest of Middle East and Africa

        13.2.2. By Type

        13.2.3. By Disease

        13.2.4. By End-use

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Disease

        13.3.4. By End-use

    13.4. Key Takeaways

14. Key Countries Viral Vector Development Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Type

            14.1.2.2. By Disease

            14.1.2.3. By End-use

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Type

            14.2.2.2. By Disease

            14.2.2.3. By End-use

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Type

            14.3.2.2. By Disease

            14.3.2.3. By End-use

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Type

            14.4.2.2. By Disease

            14.4.2.3. By End-use

    14.5. Argentina

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Type

            14.5.2.2. By Disease

            14.5.2.3. By End-use

    14.6. Chile

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Type

            14.6.2.2. By Disease

            14.6.2.3. By End-use

    14.7. Peru

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Type

            14.7.2.2. By Disease

            14.7.2.3. By End-use

    14.8. Germany

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Type

            14.8.2.2. By Disease

            14.8.2.3. By End-use

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Type

            14.9.2.2. By Disease

            14.9.2.3. By End-use

    14.10. France

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Type

            14.10.2.2. By Disease

            14.10.2.3. By End-use

    14.11. U.K.

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Type

            14.11.2.2. By Disease

            14.11.2.3. By End-use

    14.12. Spain

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Type

            14.12.2.2. By Disease

            14.12.2.3. By End-use

    14.13. Russia

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Type

            14.13.2.2. By Disease

            14.13.2.3. By End-use

    14.14. BENELUX

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Type

            14.14.2.2. By Disease

            14.14.2.3. By End-use

    14.15. China

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Type

            14.15.2.2. By Disease

            14.15.2.3. By End-use

    14.16. Japan

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2021

            14.16.2.1. By Type

            14.16.2.2. By Disease

            14.16.2.3. By End-use

    14.17. South Korea

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2021

            14.17.2.1. By Type

            14.17.2.2. By Disease

            14.17.2.3. By End-use

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2021

            14.18.2.1. By Type

            14.18.2.2. By Disease

            14.18.2.3. By End-use

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2021

            14.19.2.1. By Type

            14.19.2.2. By Disease

            14.19.2.3. By End-use

    14.20. Turkey

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2021

            14.20.2.1. By Type

            14.20.2.2. By Disease

            14.20.2.3. By End-use

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Type

        15.3.3. By Disease

        15.3.4. By End-use

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Batavia Biosciences 

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

                16.1.1.5.2. Product Strategy

                16.1.1.5.3. Channel Strategy

        16.1.2. Cobra Biologics Ltd.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

                16.1.2.5.2. Product Strategy

                16.1.2.5.3. Channel Strategy

        16.1.3. FinVector 

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

                16.1.3.5.2. Product Strategy

                16.1.3.5.3. Channel Strategy

        16.1.4. Fujifilm

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

                16.1.4.5.2. Product Strategy

                16.1.4.5.3. Channel Strategy

        16.1.5. Genelux Corporation

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

                16.1.5.5.2. Product Strategy

                16.1.5.5.3. Channel Strategy

        16.1.6. Kaneka Eurogentec

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

                16.1.6.5.2. Product Strategy

                16.1.6.5.3. Channel Strategy

        16.1.7. Lonza Group

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

                16.1.7.5.2. Product Strategy

                16.1.7.5.3. Channel Strategy

        16.1.8. Merck KGaA

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

                16.1.8.5.2. Product Strategy

                16.1.8.5.3. Channel Strategy

        16.1.9. Oxford Biomedica plc

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

                16.1.9.5.2. Product Strategy

                16.1.9.5.3. Channel Strategy

        16.1.10. Thermo Fisher Scientific

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

                16.1.10.5.2. Product Strategy

                16.1.10.5.3. Channel Strategy

        16.1.11. Virovek Inc.

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

                16.1.11.5.2. Product Strategy

                16.1.11.5.3. Channel Strategy

        16.1.12. Vigene Biosciences Inc.

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

                16.1.12.5.2. Product Strategy

                16.1.12.5.3. Channel Strategy

        16.1.13. Sirion Biotech GmbH

            16.1.13.1. Overview

            16.1.13.2. Product Portfolio

            16.1.13.3. Profitability by Market Segments

            16.1.13.4. Sales Footprint

            16.1.13.5. Strategy Overview

                16.1.13.5.1. Marketing Strategy

                16.1.13.5.2. Product Strategy

                16.1.13.5.3. Channel Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Viral Vector Development Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Viral Vector Development Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 3: Global Viral Vector Development Market Value (US$ Mn) Forecast by Disease, 2017-2032

Table 4: Global Viral Vector Development Market Value (US$ Mn) Forecast by End-use, 2017-2032

Table 5: North America Viral Vector Development Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: North America Viral Vector Development Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 7: North America Viral Vector Development Market Value (US$ Mn) Forecast by Disease, 2017-2032

Table 8: North America Viral Vector Development Market Value (US$ Mn) Forecast by End-use, 2017-2032

Table 9: Latin America Viral Vector Development Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Latin America Viral Vector Development Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 11: Latin America Viral Vector Development Market Value (US$ Mn) Forecast by Disease, 2017-2032

Table 12: Latin America Viral Vector Development Market Value (US$ Mn) Forecast by End-use, 2017-2032

Table 13: Europe Viral Vector Development Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Europe Viral Vector Development Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 15: Europe Viral Vector Development Market Value (US$ Mn) Forecast by Disease, 2017-2032

Table 16: Europe Viral Vector Development Market Value (US$ Mn) Forecast by End-use, 2017-2032

Table 17: Asia Pacific Viral Vector Development Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 18: Asia Pacific Viral Vector Development Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 19: Asia Pacific Viral Vector Development Market Value (US$ Mn) Forecast by Disease, 2017-2032

Table 20: Asia Pacific Viral Vector Development Market Value (US$ Mn) Forecast by End-use, 2017-2032

Table 21: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Forecast by Type, 2017-2032

Table 23: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Forecast by Disease, 2017-2032

Table 24: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Forecast by End-use, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Viral Vector Development Market Value (US$ Mn) by Type, 2022-2032

Figure 2: Global Viral Vector Development Market Value (US$ Mn) by Disease, 2022-2032

Figure 3: Global Viral Vector Development Market Value (US$ Mn) by End-use, 2022-2032

Figure 4: Global Viral Vector Development Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Viral Vector Development Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 6: Global Viral Vector Development Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Viral Vector Development Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Viral Vector Development Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 9: Global Viral Vector Development Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 10: Global Viral Vector Development Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 11: Global Viral Vector Development Market Value (US$ Mn) Analysis by Disease, 2017-2032

Figure 12: Global Viral Vector Development Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 13: Global Viral Vector Development Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 14: Global Viral Vector Development Market Value (US$ Mn) Analysis by End-use, 2017-2032

Figure 15: Global Viral Vector Development Market Value Share (%) and BPS Analysis by End-use, 2022-2032

Figure 16: Global Viral Vector Development Market Y-o-Y Growth (%) Projections by End-use, 2022-2032

Figure 17: Global Viral Vector Development Market Attractiveness by Type, 2022-2032

Figure 18: Global Viral Vector Development Market Attractiveness by Disease, 2022-2032

Figure 19: Global Viral Vector Development Market Attractiveness by End-use, 2022-2032

Figure 20: Global Viral Vector Development Market Attractiveness by Region, 2022-2032

Figure 21: North America Viral Vector Development Market Value (US$ Mn) by Type, 2022-2032

Figure 22: North America Viral Vector Development Market Value (US$ Mn) by Disease, 2022-2032

Figure 23: North America Viral Vector Development Market Value (US$ Mn) by End-use, 2022-2032

Figure 24: North America Viral Vector Development Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Viral Vector Development Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 26: North America Viral Vector Development Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Viral Vector Development Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Viral Vector Development Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 29: North America Viral Vector Development Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 30: North America Viral Vector Development Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 31: North America Viral Vector Development Market Value (US$ Mn) Analysis by Disease, 2017-2032

Figure 32: North America Viral Vector Development Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 33: North America Viral Vector Development Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 34: North America Viral Vector Development Market Value (US$ Mn) Analysis by End-use, 2017-2032

Figure 35: North America Viral Vector Development Market Value Share (%) and BPS Analysis by End-use, 2022-2032

Figure 36: North America Viral Vector Development Market Y-o-Y Growth (%) Projections by End-use, 2022-2032

Figure 37: North America Viral Vector Development Market Attractiveness by Type, 2022-2032

Figure 38: North America Viral Vector Development Market Attractiveness by Disease, 2022-2032

Figure 39: North America Viral Vector Development Market Attractiveness by End-use, 2022-2032

Figure 40: North America Viral Vector Development Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Viral Vector Development Market Value (US$ Mn) by Type, 2022-2032

Figure 42: Latin America Viral Vector Development Market Value (US$ Mn) by Disease, 2022-2032

Figure 43: Latin America Viral Vector Development Market Value (US$ Mn) by End-use, 2022-2032

Figure 44: Latin America Viral Vector Development Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Viral Vector Development Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 46: Latin America Viral Vector Development Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Viral Vector Development Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Viral Vector Development Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 49: Latin America Viral Vector Development Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 50: Latin America Viral Vector Development Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 51: Latin America Viral Vector Development Market Value (US$ Mn) Analysis by Disease, 2017-2032

Figure 52: Latin America Viral Vector Development Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 53: Latin America Viral Vector Development Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 54: Latin America Viral Vector Development Market Value (US$ Mn) Analysis by End-use, 2017-2032

Figure 55: Latin America Viral Vector Development Market Value Share (%) and BPS Analysis by End-use, 2022-2032

Figure 56: Latin America Viral Vector Development Market Y-o-Y Growth (%) Projections by End-use, 2022-2032

Figure 57: Latin America Viral Vector Development Market Attractiveness by Type, 2022-2032

Figure 58: Latin America Viral Vector Development Market Attractiveness by Disease, 2022-2032

Figure 59: Latin America Viral Vector Development Market Attractiveness by End-use, 2022-2032

Figure 60: Latin America Viral Vector Development Market Attractiveness by Country, 2022-2032

Figure 61: Europe Viral Vector Development Market Value (US$ Mn) by Type, 2022-2032

Figure 62: Europe Viral Vector Development Market Value (US$ Mn) by Disease, 2022-2032

Figure 63: Europe Viral Vector Development Market Value (US$ Mn) by End-use, 2022-2032

Figure 64: Europe Viral Vector Development Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Viral Vector Development Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 66: Europe Viral Vector Development Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Viral Vector Development Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Viral Vector Development Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 69: Europe Viral Vector Development Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 70: Europe Viral Vector Development Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 71: Europe Viral Vector Development Market Value (US$ Mn) Analysis by Disease, 2017-2032

Figure 72: Europe Viral Vector Development Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 73: Europe Viral Vector Development Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 74: Europe Viral Vector Development Market Value (US$ Mn) Analysis by End-use, 2017-2032

Figure 75: Europe Viral Vector Development Market Value Share (%) and BPS Analysis by End-use, 2022-2032

Figure 76: Europe Viral Vector Development Market Y-o-Y Growth (%) Projections by End-use, 2022-2032

Figure 77: Europe Viral Vector Development Market Attractiveness by Type, 2022-2032

Figure 78: Europe Viral Vector Development Market Attractiveness by Disease, 2022-2032

Figure 79: Europe Viral Vector Development Market Attractiveness by End-use, 2022-2032

Figure 80: Europe Viral Vector Development Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Viral Vector Development Market Value (US$ Mn) by Type, 2022-2032

Figure 82: Asia Pacific Viral Vector Development Market Value (US$ Mn) by Disease, 2022-2032

Figure 83: Asia Pacific Viral Vector Development Market Value (US$ Mn) by End-use, 2022-2032

Figure 84: Asia Pacific Viral Vector Development Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Viral Vector Development Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 86: Asia Pacific Viral Vector Development Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Viral Vector Development Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Viral Vector Development Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 89: Asia Pacific Viral Vector Development Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 90: Asia Pacific Viral Vector Development Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 91: Asia Pacific Viral Vector Development Market Value (US$ Mn) Analysis by Disease, 2017-2032

Figure 92: Asia Pacific Viral Vector Development Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 93: Asia Pacific Viral Vector Development Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 94: Asia Pacific Viral Vector Development Market Value (US$ Mn) Analysis by End-use, 2017-2032

Figure 95: Asia Pacific Viral Vector Development Market Value Share (%) and BPS Analysis by End-use, 2022-2032

Figure 96: Asia Pacific Viral Vector Development Market Y-o-Y Growth (%) Projections by End-use, 2022-2032

Figure 97: Asia Pacific Viral Vector Development Market Attractiveness by Type, 2022-2032

Figure 98: Asia Pacific Viral Vector Development Market Attractiveness by Disease, 2022-2032

Figure 99: Asia Pacific Viral Vector Development Market Attractiveness by End-use, 2022-2032

Figure 100: Asia Pacific Viral Vector Development Market Attractiveness by Country, 2022-2032

Figure 101: Middle East and Africa Viral Vector Development Market Value (US$ Mn) by Type, 2022-2032

Figure 102: Middle East and Africa Viral Vector Development Market Value (US$ Mn) by Disease, 2022-2032

Figure 103: Middle East and Africa Viral Vector Development Market Value (US$ Mn) by End-use, 2022-2032

Figure 104: Middle East and Africa Viral Vector Development Market Value (US$ Mn) by Country, 2022-2032

Figure 105: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 106: Middle East and Africa Viral Vector Development Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: Middle East and Africa Viral Vector Development Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Analysis by Type, 2017-2032

Figure 109: Middle East and Africa Viral Vector Development Market Value Share (%) and BPS Analysis by Type, 2022-2032

Figure 110: Middle East and Africa Viral Vector Development Market Y-o-Y Growth (%) Projections by Type, 2022-2032

Figure 111: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Analysis by Disease, 2017-2032

Figure 112: Middle East and Africa Viral Vector Development Market Value Share (%) and BPS Analysis by Disease, 2022-2032

Figure 113: Middle East and Africa Viral Vector Development Market Y-o-Y Growth (%) Projections by Disease, 2022-2032

Figure 114: Middle East and Africa Viral Vector Development Market Value (US$ Mn) Analysis by End-use, 2017-2032

Figure 115: Middle East and Africa Viral Vector Development Market Value Share (%) and BPS Analysis by End-use, 2022-2032

Figure 116: Middle East and Africa Viral Vector Development Market Y-o-Y Growth (%) Projections by End-use, 2022-2032

Figure 117: Middle East and Africa Viral Vector Development Market Attractiveness by Type, 2022-2032

Figure 118: Middle East and Africa Viral Vector Development Market Attractiveness by Disease, 2022-2032

Figure 119: Middle East and Africa Viral Vector Development Market Attractiveness by End-use, 2022-2032

Figure 120: Middle East and Africa Viral Vector Development Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Viral Vector Development Market

Published : March 2022

Healthcare

Swab and Viral Transport Medium Market

Published : March 2022

Healthcare

Cell Line Development Services Market

Published : July 2017

Healthcare

Virology Market

Published : March 2022

Google translate

Viral Vector Development Market